Catia Marzolini
Overview
Explore the profile of Catia Marzolini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
141
Citations
2372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haefliger D, Mina L, Guidi M, Marzolini C, Thoueille P, Rothuizen L, et al.
J Antimicrob Chemother
. 2025 Jan;
80(3):840-847.
PMID: 39821648
Background: Model-informed precision dosing (MIPD) combines population pharmacokinetic knowledge with therapeutic drug monitoring (TDM) to optimize dosage adjustment. It could improve target concentration attainment over empirical TDM, still widely practised...
2.
Thoueille P, Marzolini C, Guidi M, Cavassini M, Decosterd L
Clin Infect Dis
. 2024 Dec;
PMID: 39673169
No abstract available.
3.
Thoueille P, Saldanha S, Schaller F, Choong E, Veuve F, Munting A, et al.
Front Pharmacol
. 2024 Dec;
15:1437400.
PMID: 39619609
Background: The pharmacokinetics of long-acting rilpivirine has mostly been studied in clinical trials, which do not fully address the uncertainties that arise in routine clinical situations. Aims And Methods: Our...
4.
Seydoux C, Briki M, Wagner A, Choong E, Guidi M, Carrara S, et al.
Chemotherapy
. 2024 Nov;
:1-10.
PMID: 39510060
Background: Despite major advances in cancer treatment in the past years, there is a need to optimize chemotherapeutic drug dosing strategies to reduce toxicities, suboptimal responses, and the risk of...
5.
Berton M, Stader F, Bettonte S, Battegay M, Marzolini C
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae585.
PMID: 39439743
Background: The World Health Organization is pushing to accelerate the study of new human immunodeficiency virus drugs in pregnant women. However, regulatory guidelines do not specify when to conduct pharmacokinetic...
6.
Marzolini C, Gibbons S, Seddon D, Khoo S
Expert Opin Drug Metab Toxicol
. 2024 Oct;
21(2):161-172.
PMID: 39411777
Introduction: Lenacapavir is the first HIV-1 capsid inhibitor administered subcutaneously twice yearly. While lenacapavir is currently only indicated as salvage therapy, it has the potential to become a foundation of...
7.
Abela I, Chammartin F, Amstutz A, Surial B, Ballif M, Marzolini C, et al.
Open Forum Infect Dis
. 2024 Sep;
11(9):ofae502.
PMID: 39296341
The REPRIEVE trial suggests that primary cardiovascular disease (CVD) prevention could be considered among people with HIV at low CVD risk. We found cisgender women with low/moderate and high CVD...
8.
Courlet P, Spaggiari D, Cavassini M, Du Pasquier R, Saldanha S, Buclin T, et al.
Clin Mass Spectrom
. 2024 Aug;
8:8-20.
PMID: 39192990
Nucleoside reverse transcriptase inhibitors (NRTIs) have been the first class of antiretroviral drugs used against HIV infection. Despite NRTI-free regimens have been eagerly sought over the years in an effort...
9.
Haefliger D, Chehade H, Livio F, Rodrigues-Veiga V, Diezi L, Marzolini C
Semin Dial
. 2024 Aug;
37(6):461-465.
PMID: 39174700
Background: Bacterial peritonitis is a common complication of peritoneal dialysis. In the absence of systemic signs of infection, adult guidelines recommend treatment with intraperitoneal vancomycin either as empiric coverage of...
10.
Bongiovanni M, Thoueille P, Barda B, Mercier T, Marzolini C, Ramponi N, et al.
Eur J Clin Microbiol Infect Dis
. 2024 May;
43(7):1503-1504.
PMID: 38740656
No abstract available.